
|Videos|December 26, 2017
Dr. Voss on the Future of Clinical Trials for Kidney Cancer
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.
Advertisement
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.
According to Voss, collaboration is important for the neoadjuvant concepts that are being developed. It is important discuss systemic therapies in a surgical context and as a multidisciplinary effort.
The key to successful development of approaches is to have a multidisciplinary team involved, says Voss.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































